Expanded Access for KHK2455
NCT04321694 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2024-04-25
Summary
This is an expanded access program for eligible participants. This program is designed to provide access to KHK2455 in combination with Mogamulizumab prior to the approval by the local regulatory agency. A medical doctor must decide whether the potential benefit outweighs the risk of receiving this investigational therapy based on the individual patients medical history and eligibility criteria.
Conditions
Interventions
- DRUG
-
KHK2455
Sponsors & Collaborators
-
University of New Mexico Cancer Center
collaborator OTHER -
Kyowa Kirin, Inc.
lead INDUSTRY
Eligibility
- Sex
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study
NCT06622434 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Low Dose Radiation Therapy for Glioblastoma Multiforme
NCT01466686 ·Status: COMPLETED ·Phase: PHASE2
-
A Vaccine Trial for Low Grade Gliomas
NCT02358187 ·Status: RECRUITING ·Phase: PHASE2
-
AZD8055 for Adults With Recurrent Gliomas
NCT01316809 ·Status: COMPLETED ·Phase: PHASE1
-
A Dose-Escalation Study in Participants With Recurrent Malignant Glioma
NCT01682187 ·Status: COMPLETED ·Phase: PHASE1
-
Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients
NCT00024557 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients
NCT07185880 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas
NCT06687681 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases
NCT07268053 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas
NCT03134131 ·Status: NO_LONGER_AVAILABLE
-
G207 Followed by Radiation Therapy in Malignant Glioma
NCT00157703 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype Glioblastomas
NCT06824662 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Biological Therapy in Treating Patients With Glioblastoma Multiforme
NCT00003185 ·Status: COMPLETED ·Phase: PHASE2
-
Targeted Pediatric High-Grade Glioma Therapy
NCT05839379 ·Status: RECRUITING
-
Access Protocol for MAB-425 Radiolabeled With I-125 for High Grade Gliomas
NCT01317888 ·Status: UNKNOWN ·Phase: NA
-
Expanded Access to Gallium Maltolate (GaM)
NCT06404034 ·Status: NO_LONGER_AVAILABLE
-
A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions
NCT06072586 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly
NCT05565521 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
NCT06815029 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
NCT01268566 ·Status: COMPLETED ·Phase: PHASE2
-
A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG)
NCT06519682 ·Status: RECRUITING ·Phase: NA
-
A Study to Evaluate the Safety, Tolerance and Initial Efficacy of EGFRvIII CAR-T on Glioblastoma
NCT05802693 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
NCT04489420 ·Status: TERMINATED ·Phase: PHASE1
-
Study of Intraparenchymal Therapy With Irinotecan Drug Eluting Beads as Adjunct to Recurrent Surgically Resectable High Grade Glioma
NCT02481960 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
NCT01975701 ·Status: COMPLETED ·Phase: PHASE2